Issue 81

The inaugural PSYCH Symposium – Europe’s premier psychedelic healthcare conference

On Wednesday, 11 May, thought leaders from across psychedelic healthcare converged at the National Gallery for the inaugural, and sold out, PSYCH Symposium.

PSYCH Symposium: London 2022 took place against the backdrop of a deepening mental health crisis, with a surge in clinical trials demonstrating the potential of psychedelic medicines.

The seminal event provided a platform for landmark research briefings, regulatory updates and topical debates, which helped shape the future of psychedelic medicine.

READ MORE

CSIRO SHOWS SUPPORT FOR PSYCHEDELIC HEALTHCARE

CSIRO, Australia’s national science agency, aims to develop psychedelic treatments for mental health issues.

Read More

THE DISPUTE OVER A HIGH-PROFILE PSYCHEDELIC STUDY

As psychedelic research expands, so does discussion on the protocols used to demonstrate efficacy.

Read More

BUSINESS AND INVESTMENT

Filament Health reports Q1 2022 financial results.

Mydecine reports Q1 2022 financial results.

MindMed announces at-the-market share offering.

Beckley Retreats launches in Jamaica.

Investment opportunities in psychedelic healthcare.

Field Trip partners with Nue Life for psychedelic telehealth.

Numinus approved to provide psilocybin-assisted therapy.

Havn partners with non-profit Therapsil on patient access.

SCIENCE AND RESEARCH

The potential dangers of ketamine telehealth services.

The potential of psychedelic medicine.

REGULATION AND LEGISLATION

Senators push federal officials for update on psychedelic healthcare reform.

Partner with us